Predictors of adverse long-term outcome in acute myocardial infarction patients undergoing primary percutaneous transluminal coronary angioplasty - With special reference to the admission concentration of lipoprotein (a)

Circulation Journal

Volumn 67, Issue 7, 2003, Pages 605-611

  Igarashi, Yutaka ^a   Aizawa, Yoshiyasu ^a,b   Satoh, Tadashi ^a   Konno, Taku ^a   Ojima, Kenji ^a   Aizawa, Yoshifusa ^b  

^a Municipal Shonai Hosp   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Acute myocardial infarction; Lipoprotein(a); Percutaneous transluminal coronary angioplasty; Prognosis

Indexed keywords

LIPOPROTEIN A;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0038268819     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.67.605     Document Type: Article

References (43)

1. Bostom AG, Gagnon DR, Cupples LA, illson PWF, Jenner JL, Ordovas JM, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: The Framingham heart study. Circulation 1994; 90: 1688-1695.
2. Budde T, Fechtrup C, Bosenberg E, Vielhauer C, Enbergs A, Schulte H, et al. Plasma Lp (a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb 1994; 14: 1730-1736.
3. Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke T, Abu-Lebdeh HS. Predictive value of electrophoretically detected lipoprotein (a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997; 96: 1390-1397.
4. Schwarzman RA, Cox ID, Poloniecki J, Crook R, Seymour CA, Kaski IC. Elevated plasma lipoprotein (a) is associated with coronary artery disease in patients with chronic stable angina pectoris. J Am Coll Cardiol 1998; 31: 1260-1266.
5. Fujino A, Watanabe T, Kunii H, Yamaguchi N, Yoshinari K, Watanabe Y, et al. Lipoprotein (a) is a potential coronary risk factor. Jpn Circ J 2000; 64: 51-56.
6. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a). Circulation 1995; 91: 948-950.
7. Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein (a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995; 91: 1403-1409.
8. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, et al. Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283: 1845-1852.
9. Hearn JA, Donohue BC, Ba'albaki H, Douglas JS, King SB, Lembo NJ, et al. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1992; 69: 736-739.
10. Cooke T, Sheahan R, Foley D, Reilly M, D'Arcy G, Jauch W. et al. Lipoprotein (a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation 1994; 89: 1593-1598.
11. Yamamoto H, Imazu M, Yamabe T, Ueda H, Hattori Y, Yamakado M. Risk factors for restenosis after percutaneous transluminal coronary angioplasty: Role of lipoprotein (a). Am Heart J 1995; 130: 1168-1173.
12. Miner SES, Hegele RA, Sparkes J, Teitel JM, Bowman KA, Connelly PW, et al. Homocysteine, lipoprotein (a), and restenosis after percutaneous transluminal coronary angioplasty: A prospective study. Am Heart J 2000; 140: 272-278.
13. Garcia E, Elizaga J, Perez-Castellano N, Serrano JA, Soriano J, Abeytua M, et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am Coll Cardiol 1999; 33: 605-611.
14. Holmes DR, White HD, Pieper KS, Ellis SG, Califf RM, Topol EJ. Effect of age on outcome with primary angioplasty versus thrombolysis. J Am Coll Cardiol 1999; 33: 412 -419.
15. Nunn CM, O'Neill WW, Rothbaum D, Stone GW, O'Keefe J, Overlie P, et al. Long-term outcome after primary angioplasty: Report from the primary angioplasty in myocardial infarction (PAMI-I) trial. J Am Coll Cardiol 1999; 33: 640-646.
16. Hannan EL, Racz MJ, Arani DT, Ryan TJ, Walford G, McCallister BD. Short- and long-term mortality for patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1194-1201.
17. Zahn R, Schiele R, Schneider S, Gitt AK, Wienbergen H, Seidl K, et al. Decreasing hospital mortality between 1994 and 1998 in patients with acute myocardial infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis. J Am Coll Cardiol 2000; 36: 2064-2071.
18. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, et al. Fifteen-year trend in the treatment and outcome of acute myocardial infarction in Japan. Circ J 2002; 66: 178-181.
19. Cohen M, Rentrop KP. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary occlusion in human subjects: A prospective study. Circulation 1986; 74: 469-476.
20. Chesebro JH, Knatterup G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-154.
21. Igarashi Y, Yamazoe M, Shibata A. Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina. Am Heart J 1991; 121: 1094-1100.
22. Igarashi Y, Yamaura M, Ito M, Inuzuka H, Ojima K, Aizawa Y. Elevated serum lipoprotein (a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: A transesophageal echocardiographic study. Am Heart J 1998; 136: 965-971.
23. Hartzler GO, Rutherford BD, McConahay DR, Johnson WL, McCallister BD, Gura GM, et al. Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarction. Am Heart J 1983; 106: 965-973.
24. Pepine CJ, Prida X, Hill JA, Feldman RL, Conti CR. Percutaneous transluminal coronary angioplasty in acute myocardial infarction. Am Heart J 1984; 107: 820-822.
25. Stone GW, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: The primary angioplasty in myocardial infarction (PAMI) trial. J Am Coll Cardiol 1995; 25: 370-377.
26. Saito D, Shiraki T, Oka T, Kajiyama A, Takamura T. Risk factors indicating recurrent myocardial infarction after recovery from acute myocardial infarction. Circ J 2002; 66: 877-880.
27. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1202-1209.
28. Kinlay S, Epid DC, Dobson AJ, Heller RF, McElduff P, Alexander H, et al. Risk of primary and recurrent acute myocardial infarction from lipoprotein (a) in men and women. J Am Coll Cardiol 1996; 28: 870-875.
29. Seed M, Ayres KL, Humphries SE, Miller JM. Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. Am J Med 2001; 110: 22-27.
30. Wehinger A, Kastrati A, Elezi S, Baum H, Braun S, Neumann F, et al. Lipoprotein (a) and coronary thrombosis and restenosis after stent placement. J Am Coll Cardiol 1999; 33: 1005-1012.
31. Von Echardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein (a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37: 434-439.
32. Cobbaert C, Jukema JW, Zwinderman AH, Withagen AJAM, Lindemans J, Bruschke AVG. Modulation of lipoprotein (a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. J Am Coll Cardiol 1997; 30: 1491-1499.
33. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao X, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA 1995; 274: 1771-1774.
34. Niendoef A, Rath M, Wolf K, Peters S, Arps H, Beisiegel U, et al. Morphological detection and quantification of lipoprotein (a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Arch 1990; 417: 105-111.
35. Ichikawa K, Nakagawa K, Hirano K, Sueishi K. The localization of tissue factor and apoprotein (a) in atherosclerotic lesions of the human aorta and their relation to fibrinogen-fibrin transition. Pathol Res Pract 1996; 192: 224-232.
36. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801-809.
37. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon T. Macrophage infiltration in acute coronary syndromes: Implications for plaque rupture. Circulation 1994; 90: 2844-2850.
38. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, et al. Human monocyte derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-1569.
39. Dangas G, Mehran R, Harpel PC, Sharma SK, Marcovina AM, Dube G, et al. Lipoprotein (a) and inflammation in human coronary atheroma: Association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32: 2035-2042.
40. Poon M, Zhang X, Dunsky K, Taubman MB, Harpel PC. Apolipoprotein (a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997; 96: 2514-2519.
41. Walter DH, Fichtlscherer S, Britten MB, Rosin P, Auch-Achwelk W, Schachinger V, et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 2001; 38: 2006-2012.
42. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-466.
43. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein (a) as an acute phase protein. Atherosclerosis 1989; 78: 145-150.